MedTrace Logo

A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

NCT06839105 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 214

Last updated 2025-05-31

No results posted yet for this study

Summary

The purpose of this phase I clinical study was to evaluate the safety and tolerability of AWT020 monotherapy and combination with other antitumor therapies in patients with advanced malignancies

Conditions

  • Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor

Interventions

DRUG

Taxol

135\~175 mg/m2, Q3W

DRUG

Cisplatin or Carboplatin

Cisplatin(75 mg/m2, Q3W) or Carboplatin (AUC=5\~6, Q3W)

DRUG

Pemetrexed

500 mg/m2, Q3W

DRUG

Oxaliplatin

130 mg/m2, Q3W

DRUG

Capecitabine

1000 mg/m2, BID, day1-14, oral, q3w

DRUG

Bevacizumab

7.5 mg/kg, Q3W

DRUG

Renvastinib

8mg or 20mg, QD

DRUG

AWT020

q3w or q2w, i.v.

Sponsors & Collaborators

  • Shanghai Junshi Bioscience Co., Ltd.

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-21
Primary Completion
2028-04-30
Completion
2028-04-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06839105 on ClinicalTrials.gov